AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03282474 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sofosbuvir
Description: Sofosbuvir 400 MG Oral Tablet \[Sovaldi\]
Study NCT01383135 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: F18-FPPRGD2
Description: Radiopharmaceutical administered for imaging, up to 14 mCi intravenous (IV).
Study NCT01383135 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: F18-FPPRGD2
Description: Radiopharmaceutical administered for imaging, up to 14 mCi intravenous (IV).
Study NCT00972972 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: bilberry (European blueberries) and red grape juice
Description: Intervention juice: 50/50 combination of 300 ml bilberry (European blueberries) and red grape juice (Merlot grapes; Vitis Vinifera L.) per day for 9 weeks
Study NCT00972972 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo juice
Description: Placebo juice: 300 ml, similar to the intervention juice as to taste, energy, salt, and carbohydrates
Study NCT01324128 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PA21 (2.5 g tablet containing 500 mg iron)
Description: Dose range of 5.0 g/day (2 tablets/day) to 15.0 g/day (6 tablets/day).
Study NCT01324128 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sevelamer carbonate
Description: Dose range of 2.4 g/day (3 tablets/day) to 14.4 g/day (18 tablets/day)
Study NCT01324128 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: PA21-1 (1.25 g tablet containing 250 mg iron)
Description: Low dose comparator (1.25 g/day)
Study NCT02370550 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclosporin A
Description: CsA 2-3 mg/kg/d, BID PO
Study NCT02370550 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Prednisone 0.5mg/kg/d QD PO starting at Week 0. After 2-4 weeks, the initial dose is gradually tapered by 2.5 mg each week until a maintenance dosage of 5-7.5 mg/d through week 52 (visit 6). The initial and maintenance doses are determined by the investigators of each center depending on the patients.
Study NCT02370550 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Prednisone
Description: Prednisone 0.5mg/kg/d QD PO starting at Week 0. After 2-4 weeks, the initial dose is gradually tapered by 2.5 mg each week until a maintenance dosage of 5-7.5 mg/d through week 52 (visit 6). The initial and maintenance doses are determined by the investigators of each center depending on the patients.
Study NCT02370550 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablet 2-3 mg/kg/d, BID PO
Study NCT02370550 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Calcium carbonate D
Description: Calcium carbonate D 600 mg, QD PO
Study NCT02450955 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Massage
Description: A superficial massage was performed for 10 minutes in the cervical region consisting of gentle rubbing and kneading, five minutes prone and five minutes supine with a focus on cervical and suboccipital muscles in order to induce a global relaxation of the cervical and suboccipital region. Resting position. After the treatment, both groups rested for 10 minutes in a supine position with neutral ranges of neck flexion, extension, lateral flexion, and rotation.
Study NCT02450955 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Occiput-Atlas-Axis Technique
Description: This technique was applied as described previously and is used with the aim of restoring joint mobility between the occiput, atlas and axis. It is a structural technique applied bilaterally, performed on a vertical axis passing through the dens process of the axis without extension or flexion and very little side-bending. After the treatment, both groups rested for 10 minutes in a supine position with neutral ranges of neck flexion, extension, lateral flexion, and rotation.
Study NCT01952405 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Dialectical behavior therapy (DBT)
Description: Dialectical behavior therapy (DBT), developed by Marsha Linehan, has gained widespread popularity as a treatment for BPD, and its efficacy has been demonstrated in several trials.
Study NCT00745823 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Comparator: Raltegravir 400 mg b.i.d.
Description: Raltegravir 400 mg tablet by mouth (PO) twice daily (b.i.d.) + two raltegravir placebo tablets + one tablet of TRUVADA™ once daily (q.d.)
Study NCT00745823 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Experimental: Raltegravir 800 mg q.d.
Description: Raltegravir 800 mg tablet PO q.d. + two raltegravir placebo tablets + one tablet TRUVADA™ q.d.
Study NCT00745823 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TRUVADA™
Description: One tablet TRUVADA™ q.d. (fixed combination 200 mg emtricitabine and 300 mg tenofovir disoproxil fumarate)
Study NCT00745823 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TRUVADA™
Description: One tablet TRUVADA™ q.d. (fixed combination 200 mg emtricitabine and 300 mg tenofovir disoproxil fumarate)
Study NCT03613545 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: fecal microbiota transplantation
Description: 200 mL of prepared fecal microbiota suspension from heathy donors' fresh feces was injected into the colon
Study NCT03613545 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Infusion of sham
Description: Infusion of sham
Study NCT03613545 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: probiotics, antibiotics or antidepressants
Description: Drugs such as probiotics, antibiotics, antidepressants
Study NCT03200405 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DynaMeshVisible
Description: The umbilical hernias will be fixed with a mesh. In this group a MRI-visible mesh will be used.
Study NCT03200405 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: DynaMeshCICAT
Description: The umbilical hernias will be fixed with a mesh. In this group a non-visible mesh will be used.
Study NCT02968901 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: macitentan
Description: used in open label
Study NCT02370550 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Calcium carbonate D
Description: Calcium carbonate D 600 mg, QD PO
Study NCT02968901 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tadalafil
Description: used in open label
Study NCT02519036 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ISIS 443139 10 mg
Description: ISIS 443139, 10 mg, was administered by intrathecal injection, on Study Days 1, 29, 57, and 85.
Study NCT02519036 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ISIS 443139 30 mg
Description: ISIS 443139, 30 mg, was administered by intrathecal injection, on Study Days 1, 29, 57, and 85.
Study NCT02519036 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ISIS 443139 60 mg
Description: ISIS 443139, 60 mg, was administered by intrathecal injection, on Study Days 1, 29, 57, and 85.
Study NCT02519036 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ISIS 443139 90 mg
Description: ISIS 443139, 90 mg, was administered by intrathecal injection, on Study Days 1, 29, 57, and 85.
Study NCT02519036 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ISIS 443139 120 mg
Description: ISIS 443139, 120 mg, was administered by intrathecal injection, on Study Days 1, 29, 57, and 85.
Study NCT02519036 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo was administered by intrathecal injection, on Study Days 1, 29, 57, and 85.
Study NCT03159767 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ViMove Spinal Sensor
Description: Sensors will be used to measure spinal movement
Study NCT04803370 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Convalescent Plasma with antibody against SARS-CoV-2.
Description: Convalescent plasma plus standard treatment for COVID-19. The convalescent plasma is from patients recovered from COVID-19 and negative viremia in the test detection COVID-19.~The infusions will be given on days 1 and 2, of the study, after the positive result for COVID-19 of the recipient patient.
Study NCT04803370 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Standard treatment for COVID-19
Description: The patients will receive the standard treatment for COVID-19, according to guidelines for COVID-19 (retrovirals drugs, interferon-α / β, anti-Interleukin-6 monoclonal antibody, oxygen therapy, etc..)
Study NCT02418702 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.2 mg/kg ketamine
Description: 20 patients will randomly be assigned 0.2 mg/kg of Ketamine
Study NCT02418702 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 20 patients will randomly be assigned a placebo
Study NCT02073760 — intervention group
Intervention type: OTHER
Intervention: There is no intervention. The investigators are interviewing cardiac surgery staff with knowledge of infection prevention.
Description: The investigators will conduct tape recorded interviews with hospital staff about infection prevention.
Study NCT01671891 — intervention group
Intervention type: RADIATION
Intervention: radiation therapy
Description: 45-55Gy
Study NCT01955096 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: fast-track surgery
Description: The included patients will be randomly divided to two groups :30 that will undergo LAG with FTS rehabilitation programme and 31 that also will undergo LAG but receive conventional postoperative care.Laparoscopy-assisted gastrectomy will be carried out in this approach.There will be no difference in the surgical procedures of both groups.The criteria for discharge are: tolerance of solid diet, return of bowel habits and ability to walk on their own.
Study NCT01955096 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: conventional postoperative care
Description: The included patients will be randomly divided to two groups :30 that will undergo LAG with FTS rehabilitation programme and 31 that also will undergo LAG but receive conventional postoperative care.Laparoscopy-assisted gastrectomy will be carried out in this approach.There will be no difference in the surgical procedures of both groups.The criteria for discharge are: tolerance of solid diet, return of bowel habits and ability to walk on their own.
Study NCT01419678 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: collection of blood samples for PK testing
Description: PK samples collected around dosing of posaconazole
Study NCT00769470 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: trastuzumab
Description: Given IV
Study NCT00769470 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: trastuzumab
Description: Given IV
Study NCT00769470 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: carboplatin
Description: Given IV
Study NCT00769470 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: Given IV
Study NCT00769470 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: docetaxel
Description: Given IV
Study NCT00769470 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel
Description: Given IV
Study NCT00769470 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lapatinib ditosylate
Description: Given orally
Study NCT01671891 — intervention group
Intervention type: DRUG
Intervention: capecitabine (625mg/m2,bid,d1-5 qw)and oxaliplatin (85mg/m2 d1 qw)
Description: radiotherapy concurrent chemotherapy(capecitabine+oxaliplatin)
Study NCT01668134 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic radiation
Study NCT04203017 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: allogeneic fecal microbiota
Description: All patients receive autoHSCT with RIC (Cyclophosphamide, Antithymocyte globulin, Rituximab). After immune system reconstitution (approximately starting D+60 up to D+120), patients will receive FMT from healthy donor via po capsules.
Study NCT04337723 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ABI/WIFI scoring
Description: The initial ABI training workshop will be coordinated by the non-physician clinic staff champion, and all non-provider clinic staff will be asked to participate. The PI and a research assistant will conduct a 1.5-hour telemedicine training session instructing clinical staff in ABI measurement and WIfI and scoring, using the clinical scoring sheet. Following didactic teaching, participants will perform ABI tests under the guidance of the PI/research assistant and with the support of other participants. During each part of the workshop, specific attention will be directed to pitfalls and technical errors of the test. A pre-post assessment will be used to ensure comprehension of key concepts and performance of the ABI and WIfI tools.
Study NCT03930303 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Multimedia- based patient education
Description: Patients will receive a 5 minutes video education before D\&C
Study NCT02998255 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Single dose of 2L PEG
Description: Patients at average risk for inadequate BP were given instructions for bowel preparation through phone call a day before scheduled colonoscopy. Patients began to drink 2 L of PEG 4-6 hours before colonoscopy at a rate of 250 mL every 15 minutes.
Study NCT02998255 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Split dose of 4L PEG
Description: All patients at average risk for inadequate BP were given instructions for bowel preparation through phone call a day before scheduled colonoscopy. the participants began to drink the first 2 L of PEG at 7:00-9:00 PM on the day before colonoscopy at a rate of 250 mL every 15 minutes. On the day of the procedure, patients took the remaining 2 L 4-6 hours before colonoscopy.
Study NCT03275012 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gabapentin + Morphine
Description: Gabapentin: liquid oral formulation (syrup) - 75 mg/ml-three times daily. The starting dose during the optimization period will be defined according to 2 weight groups (5-15kg and >15kg). Dose will be scaled at Day 1,3,5,14,and 21 according to a specific schedule. Maintenance dosing will be scheduled in accordance to the body weight.~Morphine: background therapy as oral, liquid and solid formulations. Patients with BW≤30kg :liquid oral formulation four times daily throughout the whole treatment period. Patients with BM>30kg : immediate release solid and/or liquid oral formulation four times daily during titration phase and an extended release solid oral formulation twice daily during the maintenance period.
Study NCT03275012 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo + Morphine
Description: Placebo liquid oral formulation. Morphine: background therapy as oral, liquid and solid formulations. Patients with BW≤30kg :liquid oral formulation four times daily throughout the whole treatment period. Patients with BM>30kg : immediate release solid and/or liquid oral formulation four times daily during titration phase and an extended release solid oral formulation twice daily during the maintenance period.
Study NCT02637284 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bepecin
Description: Phase 1a: Healthy volunteers will take a single dose of 1, 3 or 6 tablets by mouth of PCO-02 containing 1 mg of Bepecin to study safety and pharmacokinetics.~Phase 1b: All subjects will take 3 tablets of PCO-02 containing 1 mg of Bepecin every 8 hours during two weeks, to study safety and pharmacokinetics.
Study NCT02637284 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Phase 1 a: Healthy volunteers will take a single dose of 1, 3 or 6 tablets by mouth of PCO-03 (placebo) as a control group.~Phase 1b: All subjects will take 3 tablets of PCO-03 (placebo) every 8 hours during two weeks, as a control group.
Study NCT05718453 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Laboratory Tests
Description: Measurement of serum level of CRP, tumor necrosis factor, zinc, copper, potassium, sodium, and magnesium in patients with stable COPD and during exacerbation.
Study NCT01832649 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Supervised moderate-vigorous exercise in group, based on strength and calisthenics exercises, 2 times per week during 8 weeks.
Study NCT01832649 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Health education
Description: Supervised groups 2 times per week during 8 weeks.
Study NCT01619982 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cefazolin 25 mg/kg body weight and Vancomycin hydrochloride
Description: Cefazolin 25 mg/kg/dose administered intravenously over 5 minutes within 60 minutes of surgical incision and then re-dosed (25 mg/kg: maximum 2 grams/dose) every 4 hours intra-operatively depending on the duration of surgery as per standard peri-operative prophylaxis for cardiac surgery and Vancomycin 15 mg/kg (max 1.5 gram/dose) will be administered intravenously over 1-2 hours (after completion of cefazolin infusion) For patients younger than 1 month of age, a one-time repeat dose of 15 mg/kg can be given intraoperatively 12 hours after the beginning of the first vancomycin dose if the procedure is > 12 hours in duration. For patients equal to or older than 1 month, a one-time repeat dose of 15 mg/kg (max 1.5 grams) will be given intra-operatively 8 hours after the beginning of the first vancomycin dose if the procedure is > 8 hours in duration.
Study NCT01619982 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Cefazolin 30 mg/kg body weight
Description: Intervention: Drug: Cefazolin pre-operative prophylaxis~Other Names:~Cefazolin: Brand Names Ancef, Kefzol~Cefazolin 30 mg/kg/dose administered intravenously over 10 minutes within 60 minutes of surgical incision and then re-dosed (30 mg/kg: maximum 2 grams/dose) every 4 hours intra-operatively depending on the duration of surgery as per standard peri-operative prophylaxis for cardiac surgery.
Study NCT03275454 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIVV009 6.5 grams
Description: Participants who weigh less than 75 kilogram (kg) will receive fixed doses of 6.5 grams of BIVV009.
Study NCT03275454 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIVV009 7.5 grams
Description: Participants who weigh 75 kg or more will receive fixed doses of 7.5 grams of BIVV009.
Study NCT03432702 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Horizontal ridge augmentation
Description: Surgical procedures performed to provide the alveolar ridge with enough width and height to allow for the prosthetically driven implant placement.
Study NCT03432702 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Horizontal ridge augmentation
Description: Surgical procedures performed to provide the alveolar ridge with enough width and height to allow for the prosthetically driven implant placement.
Study NCT00952978 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 10 mg ilaprazole
Description: Two 5-mg ilaprazole tablets(Livzon Pharm Group Inc., China) together with one placebo capsule in a package being taken orally each morning on an empty stomach for 4 weeks
Study NCT00952978 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 20 mg omeprazole
Description: One 20-mg omeprazole capsule (AstraZeneca, Losec) together with two placebo tablets in a package being taken orally each morning on an empty stomach for 4 weeks
Study NCT02649465 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tofogliflozin
Description: The group receiving Tofogliflozin (at a dose of 20mg once daily) for 48 weeks
Study NCT02649465 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glimepiride
Description: Sulfonylurea dosage (Glimepiride): dosing from 0.5 mg for initial 4 weeks. Then, if there is no adverse effect or no improvement of glucose metabolism, glimepiride is escalated to 6 mg once daily.
Study NCT04023435 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PNE edcuation
Description: The PNE session will last 30 minutes and will be delivered in a one-on-one educational format with a clinician using prepared images, drawings and metaphors. The 30-minute PNE session was chosen to reflect a clinically meaningful intervention in a typical allocated time frame in clinical practice. The content of the PNE is described in detail elsewhere, using a metaphors to explain various aspects of pain including sensitization of the peripheral and central nervous system (sensitive alarm system metaphor); spreading pain (nosy neighbors metaphor); increases problems with focus and concentration (brain meeting metaphor) and difficulty with fatigue and sleep (lion metaphor).
Study NCT00768157 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: antiviral treatment (lamivudine or entecavir)
Description: antiviral treatment (lamivudine 100mg per day or entecavir 0.5mg per day)
Study NCT05718453 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: PLACEBO_COMPARATOR
Intervention: Laboratory Tests
Description: Measurement of serum level of CRP, tumor necrosis factor, zinc, copper, potassium, sodium, and magnesium in patients with stable COPD and during exacerbation.
Study NCT03068936 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Intensity modulated radiotherapy
Description: Intensity modulated radiotherapy once a day, 5 times a week, continuous treatment for about 6 weeks (DT 70Gy)
Study NCT03068936 — intervention group
Intervention type: RADIATION
Group type: OTHER
Intervention: Intensity modulated radiotherapy
Description: Intensity modulated radiotherapy once a day, 5 times a week, continuous treatment for about 6 weeks (DT 70Gy)
Study NCT00924612 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral testosterone undecanoate (containing 300 mg T)